Clinical trial
Potentially resectable metastatic colorectal cancer with wild-type KRAS and BRAF: alternating chemotherapy plus cetuximab - A randomised phase II trial - Nordic 7.6
Response rate (RR) estimate by the investigator
| Category | Value |
|---|---|
| Study start date | 2012-01-03 |